Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia.

J Obes · 2011 · PMC3021887 · PMID 21253513

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

In this nondiabetic population, minimal, nonsignificant changes were observed in fasting glucose and fasting insulin in both groups at 9 months, with, however, a favorable trend for rimonabant 20 mg, especially in fasting insulin. 3.4.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.